Sterling Biotech - News

NSE: STERLINBIO | BSE: 512299

₹0.70

₹0.00 (0.00%)

As on 05-Nov-2018IST

Market cap

₹21 Cr

Revenue (TTM)

₹457 Cr

P/E Ratio

--

P/B Ratio

-0

Div. Yield

0 %

Annual
Quarterly

Annual Reports

Annual Reports

2017

Annual Reports

2016

Annual Reports

2014

Annual Reports

2013

Annual Reports

2012

Annual Reports

2011

Annual Reports

2010

Annual Reports

2009

Annual Reports

2008

Annual Reports

2007

Annual Reports

2006

Annual Reports

2005

Annual Reports

2004

Annual Reports

2003

Annual Reports

2002

Annual Reports

1999

Announcements

View Announcements

Recent

Important

Intimation Of Liquidation Process As Per The Requirement Of Regulation 30 Of The Securities And Exchange Board Of India (Listing Obligations And Disclosure Requirements) Regulations 2015.

14-Nov-2022

Intimation Of Liquidation Process As Per The Requirement Of Regulation 30 Of The Securities And Exchange Board Of India (Listing Obligations And Disclosure Requirements) Regulations 2015.

14-Nov-2022

Statement Of Investor Complaints For The Quarter Ended September 2022

04-Nov-2022

Audited Financial Statement For The Financial Year 2021-22

12-Oct-2022

Statement Of Investor Complaints For The Quarter Ended June 2022

20-Jul-2022

Format of the Initial Disclosure to be made by an entity identified as a Large Corporate : Annexure A

29-Apr-2022

Intimation Of Liquidation Process As Per The Requirement Of Regulation 30 Of The Securities And Exchange Board Of India (Listing Obligations And Disclosure Requirements) Regulations 2015.

22-Apr-2022

Certificate From Practicing Company Secretary For The Year Ended March 31 2022 As Required Under Regulation 40(9) Of SEBI (Listing Obligation And Disclosure Requirements) Regulations 2015.

21-Apr-2022

Compliance Certificate As On March 31 2022 Under Regulation 7(3) Of SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015.

21-Apr-2022

Statement Of Investor Complaints For The Quarter Ended March 2022

21-Apr-2022